The 55th International Medical Exhibition MEDICA concluded successfully in Dusseldorf, Germany from 13th to16th, November. As the world's top medical device and medical technology exhibition, this event attracted a total of 6,273 medical companies from 140+ countries to bring new medical technology product chains, innovative results, and concerns about the latest medical technology trends and the development of top medical devices. Medical industry professionals, doctors, researchers, manufacturers and suppliers participated in the exhibition and visited.
Based on the core technology of microfluidics, Weikang Biotech is deeply involved in the in vitro diagnostic industry. With the core technical advantages of "small, precise and clever", Weikang Biotech continues to add quantitative testing menus for biomarkers such as premature birth, eclampsia, tumors, etc. to understand customer needs. Developed various types of single and joint testing product lines including but not limited to growth and development, anemia, thyroid function, sex hormones, infectious diseases, allergens, inflammation, diabetes, myocardium, gastric function, respiratory viruses, etc. Single testing 5 -10 minutes response time, 15 minutes for joint inspection, and a menu of up to 9 testing items was obtained. It was favored by visiting customers, who all expressed their sincere intention to cooperate.
At this event, VACURE brought microfluidic POCT products to the world audience, independently patented LYOFIA and DISKFLU fluorescence immunoassay quantitative analysis dual platforms and professional explanations, providing rich scenario solutions and comprehensive solutions for global medical and people's livelihood. The maternal and child testing menu has attracted European professional audiences, and even dealers in Italy, Germany, and the United States have reached cooperation.
After this grand event, VACURE Biotech will continue to adhere to the original intention of "protecting people's livelihood and health and assisting the development of the medical industry", and continue to provide richer scenario solutions for global medical and people's livelihood with excellent testing products, sincere attitude and professional capabilities. Please look forward to!
Precise and Flexible, True Microfluidics
Next stop, MEDLAB MIDDLE EAST 2024, VACURE Biotech sincerely invites you to see you in Dubai!
Booth: Z2.C13
Date: 2024.2.5-2.8
Address: Dubai, United Arab Emirates
About VACURE
VACURE Biotechnology is a high-tech enterprise focusing on the field of in vitro diagnostics (IVD) point-of-care testing (POCT). The company has brought together many R&D personnel (accounting for 39%) such as the Provincial Thousand Talents Plan. Based on self-developed patented core technologies such as microfluidic chip design, time-resolved fluorescent nanomaterials, and inkjet freeze-drying, it has independently developed LYOFIA® platform, microfluidic strip fluorescence immunoassay quantitative detection platform, iteratively upgraded DISKFLU® platform，a disc microfluidic immunoassay panel detection system, and deploye GENFLU microfluidic molecule integrated POCT detection system to create POCT immune and molecular products with excellent performance, realizing the integration of raw materials, instruments and the entire chain of reagents is self-developed and produced. Since 2023, it has set sail overseas and its products have been exported to 60+ countries at home and abroad.
Welcome to connect:
Email: info@vacurebiotech.com
Tel: 0086-028-85155537